Qing Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qing Wang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Yang Sun
Department of Ophthalmology, Stanford University School of Medicine
3 shared publications - Ke Ning
Department of Ophthalmology, Stanford University School of Medicine , 1651 Page Mill Road, Rm 2220, Palo Alto, CA 94304
2 shared publications - Siyu Chen
Department of Ophthalmology, Stanford University School of Medicine
2 shared publications - Zhiquan Liu
Department of Ophthalmology, Stanford University School of Medicine
2 shared publications - Biao Wang
Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, CA 94304, USA
1 shared publication Chien-Hui Lo
Department of Ophthalmology, Stanford University School of Medicine , 1651 Page Mill Road, Rm 2220, Palo Alto, CA 94304
1 shared publication
Latest Publications
- Open Access
- 9 September 2026
- Published by Wiley in Advanced Science
- p. e77704
CRISPR and Gene Augmentation Rescue Trabecular Meshwork Dysfunction in iPSC Models of Lowe Syndrome
Lowe syndrome is a rare, currently incurable multisystem disorder that affects the eyes, kidneys, and central nervous system. It is caused by mutations in the OCRL gene, which encodes an inositol 5‐phosphatase. The disorder remains incurable, and the pathways underlying the ocular symptoms remain poorly understood, largely due to the lack of appropriate models. In this study, trabecular meshwork cell models of Lowe syndrome were generated to test two distinct gene therapy strategies: a mutation‐agnostic OCRL DNA augmentation therapy and a patient‐specific CRISPR‐mediated gene correction strategy. The results showed that AAV2‐OCRL demonstrated the highest transduction efficiency in patient iPSC‐derived trabecular meshwork models (iHTM) among the three AAV‐OCRL vectors evaluated, establishing it as a promising delivery vector. Targeted CRISPR‐based gene therapy restored OCRL enzyme activity and corrected cellular defects in patient iPSC‐derived trabecular meshwork cell models. Furthermore, RNA‐sequencing analysis of these models revealed dysregulation of extracellular matrix organization, cell adhesion, focal adhesion, and cytoskeletal regulatory pathways, suggesting that disruption of interconnected ECM‐adhesion‐cytoskeletal networks may contribute to trabecular meshwork dysfunction in Lowe syndrome‐associated glaucoma. These findings indicate the feasibility of OCRL gene augmentation and CRISPR‐based gene editing in patient‐derived ocular models and position AAV2‐OCRL as a leading therapeutic candidate for Lowe syndrome.
- 9 September 2026
- Published by Wiley in Advanced Science
- p. e77704
Open AccessCRISPR and Gene Augmentation Rescue Trabecular Meshwork Dysfunction in iPSC Models of Lowe Syndrome
Lowe syndrome is a rare, currently incurable multisystem disorder that affects the eyes, kidneys, and central nervous system. It is caused by mutations in the OCRL gene, which encodes an inositol 5‐phosphatase. The disorder remains incurable, and the pathways underlying the ocular symptoms remain poorly understood, largely due to the lack of appropriate models. In this study, trabecular meshwork cell models of Lowe syndrome were generated to test two distinct gene therapy strategies: a mutation‐agnostic OCRL DNA augmentation therapy and a patient‐specific CRISPR‐mediated gene correction strategy. The results showed that AAV2‐OCRL demonstrated the highest transduction efficiency in patient iPSC‐derived trabecular meshwork models (iHTM) among the three AAV‐OCRL vectors evaluated, establishing it as a promising delivery vector. Targeted CRISPR‐based gene therapy restored OCRL enzyme activity and corrected cellular defects in patient iPSC‐derived trabecular meshwork cell models. Furthermore, RNA‐sequencing analysis of these models revealed dysregulation of extracellular matrix organization, cell adhesion, focal adhesion, and cytoskeletal regulatory pathways, suggesting that disruption of interconnected ECM‐adhesion‐cytoskeletal networks may contribute to trabecular meshwork dysfunction in Lowe syndrome‐associated glaucoma. These findings indicate the feasibility of OCRL gene augmentation and CRISPR‐based gene editing in patient‐derived ocular models and position AAV2‐OCRL as a leading therapeutic candidate for Lowe syndrome.
- Open Access
- 2 June 2025
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 4 (6) , pgaf168
Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting
Glaucoma is a major global cause of irreversible vision loss. It is marked by elevated intraocular pressure (IOP) and the loss of retinal ganglion cells (RGC). While there are medical and surgical therapies for glaucoma aiming to reduce aqueous humor production or enhance its drainage, these treatments are often inadequate for effectively managing the disease. In this study, we developed a targeted therapy for glaucoma by knocking down two genes associated with aqueous humor production (aquaporin 1 [AQP1] and carbonic anhydrase type 2 [CA2]) using Cas13 RNA editing systems. We demonstrate that hfCas13d-mediated knockdown of AQP1 and CA2 significantly lowers IOP in wild-type mice and in a corticosteroid-induced glaucoma mouse model. We show that the lowered IOP results from decreasing aqueous production without affecting the outflow facility; this treatment also significantly promotes RGC survival as compared with untreated control groups. Therefore, CRISPR–Cas-based gene editing may be an effective treatment to lower IOP for glaucomatous optic neuropathy.
- 2 June 2025
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 4 (6) , pgaf168
Open AccessGene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting
Glaucoma is a major global cause of irreversible vision loss. It is marked by elevated intraocular pressure (IOP) and the loss of retinal ganglion cells (RGC). While there are medical and surgical therapies for glaucoma aiming to reduce aqueous humor production or enhance its drainage, these treatments are often inadequate for effectively managing the disease. In this study, we developed a targeted therapy for glaucoma by knocking down two genes associated with aqueous humor production (aquaporin 1 [AQP1] and carbonic anhydrase type 2 [CA2]) using Cas13 RNA editing systems. We demonstrate that hfCas13d-mediated knockdown of AQP1 and CA2 significantly lowers IOP in wild-type mice and in a corticosteroid-induced glaucoma mouse model. We show that the lowered IOP results from decreasing aqueous production without affecting the outflow facility; this treatment also significantly promotes RGC survival as compared with untreated control groups. Therefore, CRISPR–Cas-based gene editing may be an effective treatment to lower IOP for glaucomatous optic neuropathy.
- Open Access
- 20 December 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (51) , eadn7540
dCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa
Retinitis pigmentosa (RP) is characterized by degeneration of rod and cone photoreceptors that progresses to irreversible blindness. Now, there are no mutation-agnostic approaches to treat RP. Here, we utilized a single adeno-associated virus (AAV)–based CRISPR activation system to activate phosphodiesterase 6B (Pde6b) to mitigate the severe degeneration in Pde6a nmf363 mice. We demonstrate that transcriptional activation of Pde6b can rescue the loss of Pde6a , with preservation of retinal structure, restoration of electroretinography responses, and improvement of visual function as assessed by optokinetic response and looming-induced escape behaviors. These findings demonstrate the therapeutic potential of a dCasMINI-mediated activation strategy that provides a mutation-independent treatment for retinal degeneration. This study offers a promising therapeutic approach for RP and potentially other forms of genetic diseases.
- 20 December 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (51) , eadn7540
Open AccessdCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa
Retinitis pigmentosa (RP) is characterized by degeneration of rod and cone photoreceptors that progresses to irreversible blindness. Now, there are no mutation-agnostic approaches to treat RP. Here, we utilized a single adeno-associated virus (AAV)–based CRISPR activation system to activate phosphodiesterase 6B (Pde6b) to mitigate the severe degeneration in Pde6a nmf363 mice. We demonstrate that transcriptional activation of Pde6b can rescue the loss of Pde6a , with preservation of retinal structure, restoration of electroretinography responses, and improvement of visual function as assessed by optokinetic response and looming-induced escape behaviors. These findings demonstrate the therapeutic potential of a dCasMINI-mediated activation strategy that provides a mutation-independent treatment for retinal degeneration. This study offers a promising therapeutic approach for RP and potentially other forms of genetic diseases.